Statin Dosages: Higher Doses for Cholesterol & Heart Risks
High-Intensity statins: experts Advocate for Maximum Starting Doses in High-Risk Patients
Table of Contents
New guidance suggests that individuals at high risk for heart disease should begin statin therapy at maximum dosages to effectively control LDL cholesterol and reduce cardiovascular events.
ATLANTA,GA – Leading cardiologists and researchers are urging a shift in prescribing practices,advocating for the initiation of statin therapy at maximum dosages for patients at high risk of heart disease. This approach aims to achieve more aggressive LDL cholesterol reduction, a key factor in preventing cardiovascular events.
The Case for High-Intensity Statin Therapy
Experts emphasize that for individuals with established atherosclerotic cardiovascular disease, the goal should be significant LDL cholesterol reduction. Dr. Laurence Sperling, the Katz Professor in Preventive Cardiology at the Emory University School of Medicine, highlighted that current guidelines, such as those developed in 2018 by a joint task force of the American College of Cardiology and the American Heart Association, already support this strategy.
“In patients with clinical atherosclerotic cardiovascular disease, [the guidelines say] reduce LDL cholesterol with high-intensity statin therapy or maximally tolerated statin therapy,” Dr. Sperling explained. “The more LDL cholesterol is reduced on statin therapy, the greater will be subsequent risk reduction.” He personally endorses the proposal to use “a maximally tolerated statin to lower LDL-C levels by 50%.”
Addressing Underdosing Concerns
Joseph Saseen, a researcher and professor of clinical pharmacy at the University of Colorado’s Skaggs School of Pharmacy and Pharmaceutical Sciences, identified a common reason for the underdosing of statins: cardiologists may overestimate the likelihood of side effects like muscle aches and digestive problems.
“While dose-related side effects can occur, they do not justify the routine underdosing of statins in high-risk populations,” Saseen stated. “Clinicians too often initiate therapy at suboptimal doses, particularly in patients with elevated [cardiovascular] risk.Evidence-based guidelines recommend starting high-intensity statin therapy, especially very high-risk secondary prevention patients.”
Saseen pointed to clinical data demonstrating the safety and efficacy of higher starting doses. As an example, initiating atorvastatin at up to 80 mg daily has proven effective in reducing cardiovascular events in secondary prevention patients. Similarly, rosuvastatin at 20 mg has shown to be a safe and effective starting dose for primary prevention patients with elevated high-sensitivity C-reactive protein.
Expert Consensus and Patient tolerance
Dr. Paul Heidenreich, a practicing cardiologist and professor at the Stanford University School of Medicine, concurs with the sentiment that higher starting doses are often warranted.
“When high intensity statins are indicated, one can recommend starting with the high intensity or beginning with moderate intensity followed by up-titration,” he said.
He acknowledged that some cardiologists express concern that patients unable to tolerate a high-intensity statin might afterward refuse all statins, making a moderate starting dose a safer initial approach. However, Dr.Heidenreich believes this scenario is rare.
“I feel it is rare that the patient will refuse to try a lower dose,” Heidenreich commented. “As the authors note, titration to a higher intensity is not as frequent as it should be, with patients staying on the initial intensity. Thus, patients are likely better off starting with the recommended high-intensity statin.”
He also noted that clinical data revealed a surprisingly high rate of placebo intolerance, suggesting that patients might potentially be more attuned to potential side effects when starting new medications. Crucially,he stressed that “the vast majority of patients tolerate statins medications without side effects.” This underscores the importance of adhering to evidence-based guidelines that prioritize aggressive LDL cholesterol lowering in high-risk individuals.